MINNEAPOLIS, July 29, 2024 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, announced certain preliminary, unaudited results for the quarter ended June 30, 2024, and updated full year 2024 revenue outlook. The company plans to report its complete results and host its earnings conference call for the second quarter of 202 ...

Stryker, carrying a Zacks Rank of 2 (Buy) at present, has an estimated long-term growth rate of 10.6%. SYK's earnings surpassed estimates in each of the trailing four quarters, with the average being 4.9%. Stryker has gained 17.3% against the industry's 2.9% decline in the past year. Boston Scientific, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 12.5%. BSX's earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 7.5%. Boston S ...

Company Announcement - Inspire Medical Systems announced the appointment of Melissa J Mann as Chief People Officer effective July 22 2024 [1] - Melissa J Mann brings over 25 years of experience in human capital management including 8 years at UnitedHealth Group's Optum division and 13 years at Target Corporation [2] - Melissa J Mann expressed excitement about joining Inspire to help shape the human capital strategy and strengthen the team and culture to fulfill the company's mission of prioritizing patients with untreated obstructive sleep apnea [3] Leadership Transition - Melissa J Mann is replacing Steven L Jandrich who retired in May after 6 years with Inspire during which the company grew to over 1 000 team members [5] - Tim Herbert Chairman and CEO of Inspire highlighted Melissa's vast experience in human capital management as valuable for the company's continued growth and scaling [5] Company Overview - Inspire Medical Systems is a medical technology company focused on developing and commercializing minimally invasive solutions for obstructive sleep apnea [3] - The company's proprietary Inspire therapy is the first and only FDA-approved neurostimulation technology for treating moderate to severe obstructive sleep apnea [3] Educational Background - Melissa J Mann holds a B A from 1996 and an M B A in Human Resources Management from 2003 both from the University of St Thomas in St Paul Minnesota [5]

MINNEAPOLIS, July 19, 2024 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE:INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea (OSA), today announced CE mark certification under the European Union's Medical Device Regulation (EU MDR 2017/745) for Inspire therapy. "Inspire has a long history of compliance to the European Union's (EU) quality system and CE mark requirements, ...

"Inspire has a long history of compliance to the European Union's (EU) quality system and CE mark requirements, with uninterrupted CE mark approval since 2010," said Tim Herbert, Chairman and President of Inspire. "The Inspire team has worked diligently with our notified body in Europe to complete the review process, which included obtaining temporary approval through derogation authorization to continue to deliver Inspire product in several countries." There are two changes to Inspire therapy that are now ...

Core Insights - Inspire Medical Systems has received approval from the European Union Medical Device Regulation (EU MDR) for additional MRI scan conditions, expanding its therapy's use to include full-body MRI scans, which were previously limited to head, neck, and extremity scans [1][2] - This approval is retroactive, benefiting all patients with the Inspire IV neurostimulator device that was introduced in 2018 [1] - The full-body MRI compatibility has been a significant advantage for patients in the United States for the past two years, and this new approval aims to provide similar benefits for patients in Europe [2][6] Company Overview - Inspire Medical Systems is focused on developing and commercializing innovative, minimally invasive solutions for patients with obstructive sleep apnea (OSA) [3] - The company's proprietary Inspire therapy is the first and only FDA-approved neurostimulation technology for treating moderate to severe obstructive sleep apnea [3] Market Impact - The expansion of MRI compatibility is expected to alleviate concerns for patients considering Inspire therapy, potentially increasing the adoption of the therapy among those who struggle with CPAP [2][6] - Millions of MRIs are performed annually in Europe for various medical evaluations, indicating a substantial market opportunity for Inspire's expanded therapy use [2]

NEW YORK, July 17, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Inspire Medical Systems, Inc. (NYSE: INSP) on behalf of long-term stockholders following a class action complaint that was filed against Inspire Medical on December 22, 2023 with a Class Period from May 3, 2023 to November 7, 2023. Our investigation concerns whether the board of directors of Inspire Medical have breached their fiduciary dutie ...

Company Overview - Inspire Medical Systems Inc. has issued a recall for its Inspire IV Implantable Pulse Generator (IPG) Model 3028 due to a critical manufacturing defect that can lead to electrical leakage, potentially causing severe health consequences [1][14] - The recall has been classified by the FDA as the most serious type, indicating the urgency and severity of the issue [1] Impact of the Recall - The defect in the device can result in stimulation below normal therapeutic levels, early battery depletion, and inconsistent or inappropriate stimulation, which necessitates immediate identification and correction to prevent serious health risks [3] - Following the recall announcement, shares of Inspire Medical declined by 3.3% to close at $131.44 [8] - Year-to-date, shares of Inspire Medical have decreased by 35.4%, contrasting with the industry's decline of 19.5% [10] Industry Prospects - The market for implantable pulse generators is experiencing significant growth, projected to reach $188.76 billion by 2030, with a compound annual growth rate (CAGR) of 8.6% from a valuation of $118.57 billion in 2023 [16] - Advances in medical technology and the rising incidence of neurological illnesses and chronic pain are driving the demand for smaller, more effective devices with improved battery life and wireless communication capabilities [9] Financial Performance - In the first quarter of 2024, the company reported a 25% year-over-year increase in U.S. revenues, attributed to increased market penetration of Inspire therapy [15]

There have been no reported injuries. There have been no reports of death. The IPG works with external programmers that allow the physician to set and adjust the therapy parameters and the patient to control the therapy's activation and intensity. Loading... The FDA has labeled a recall of Inspire Medical Systems, Inc.'s INSP nerve-stimulating implant for obstructive sleep apnea as Class I, the most serious kind. Inspire Medical Systems is recalling Inspire IV Implantable Pulse Generator (IPG) Model 3028 du ...

Company Overview - Inspire Medical Systems is a medical technology company focused on developing and commercializing innovative, minimally invasive solutions for patients with obstructive sleep apnea [3]. Financial Results Announcement - Inspire will release its financial results for the second quarter of 2024 after the close of trading on Tuesday, August 6 [4]. - A conference call will be hosted by Inspire's management team at 5:00 p.m. Eastern Time to discuss the financial results and recent business developments [4]. Conference Call Details - Investors can register for the conference call, and an email will be sent with dial-in details and a unique access code [1]. - A replay of the call will be available on the Company's Investor Relations website approximately two hours after the event and archived for two weeks [2]. - A webcast of the call will also be accessible via the Investor Relations page of the Inspire website [5].